Dr. Jack Regan reports

LEXAGENE ADOPTS CORPORATE GOVERNANCE CHARTERS AND POLICIES

Lexagene Holdings Inc. has adopted new corporate governance charters and policies.

Dr. Jack Regan, Lexagene's chief executive officer and founder, stated: "The board of directors, along with our leadership team, take good corporate governance seriously. The board reviewed our existing charters and policies, and felt it was time to modernize them. By doing so, we are elevating our effectiveness and moving in a direction where accountability, the ability to manage resources and improving our performance strengthen strategic business imperatives."

The board of directors adopted a new audit committee charter, a compensation committee charter, a nominating and corporate governance charter, a cybersecurity policy, and a code of business conduct and ethics. These charters and policies are available on the company's website or by contacting info@lexagene.com.

The board also announced that it has filed and obtained receipt for a final base shelf prospectus, allowing the company to offer up to $25-million of common shares, warrants, subscription receipts, debt securities or units, or any combination thereof from time to time during the 25-month period that the shelf prospectus is effective. Lexagene filed the shelf prospectus with the securities commissions in all the provinces and territories of Canada. The specific terms of any future offering of securities will be set forth in a prospectus supplement to the shelf prospectus, which will be filed with the applicable securities' regulatory authorities in connection with any such offering. A copy of the shelf prospectus can be found on SEDAR.

About Lexagene Holdings Inc.

Lexagene is a molecular diagnostic company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, for food safety and for use in open-access markets such as clinical research, agricultural testing and biodefence. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter a sample ID and press go. The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

We seek Safe Harbor.